Evidence map›Paper›PMID 27874025›Full record

ArticleScientific reports2016

Beyond Antibodies: Development of a Novel Protein Scaffold Based on Human Chaperonin 10.

Abdulkarim M Alsultan, David Y Chin, Christopher B Howard, Christopher J de Bakker, Martina L Jones, Stephen M Mahler

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Pharmaceutics · 2025
    Article
  2. Article
  3. The reduced form of the antibody CH2 domain.Protein science : a publication of the Protein Society · 2021
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Abdulkarim M AlsultanAustralian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland (UQ), Brisbane, QLD 4072, Australia.
David Y ChinAustralian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland (UQ), Brisbane, QLD 4072, Australia.
Christopher B HowardAustralian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland (UQ), Brisbane, QLD 4072, Australia.
Christopher J de BakkerAustralian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland (UQ), Brisbane, QLD 4072, Australia.
Martina L JonesAustralian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland (UQ), Brisbane, QLD 4072, Australia.
Stephen M MahlerAustralian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland (UQ), Brisbane, QLD 4072, Australia.
University of Queensland · AUAustralian Research Council · AUNational Imaging Facility · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human Chaperonin 10 (hCpn10) was utilised as a novel scaffold for presenting peptides of therapeutic and diagnostic significance. Molecular dynamic simulations and protein sizing analyses identified a peptide linker (P1) optimal for the formation of the quarternary hCpn10 heptamer structure. hCpn10 scaffold displaying peptides targeting Factor VIIa (CE76

Indexed as

Binding SitesBlood CoagulationChaperonin 10Factor VIIaHumansHyaluronan ReceptorsModels, MolecularMolecular Dynamics SimulationPeptide LibraryPeptidesPregnancy ProteinsProtein BindingProtein Structure, QuaternarySuppressor Factors, ImmunologicCD44 protein, humanChaperonin 10early pregnancy factorFactor VIIaHyaluronan ReceptorsPeptide LibraryPeptidesPregnancy ProteinsSuppressor Factors, Immunologic

Identifiers

PMID27874025
PMCPMC5118791
OpenAlexW1203630606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.